Oncology

The Monash Health Department of Oncology provides more than 1.5 million residents of southern Melbourne with access to world leading cancer treatment over three locations within the Monash Health service:

Moorabbin Hospital: Breast cancer, GI cancer, GU cancer, Lung cancer

Dandenong Hospital: General Oncology, Geriatric Oncology

Monash Health Translation Precinct (MHTP building Level 3). Monash Medical Centre, Clayton: Cancer Clinical Trials

Our Services

Cancer patients receive care from diagnosis to treatment and follow-up support. Through collaborative multidisciplinary team framework we provide the Medical Oncology aspect of cancer care, integrating with teams from surgical and radiation oncology and Palliative and Supportive care.

Our Staff


Department Head

Prof. Eva Segelov MBBS (Hons 1) PhD FRACP

Professor/Director of Oncology
Gastrointestinal Cancers Neuroendocrine Tumours

Senior Leadership Team

Associate Professor Arun Azad MBBS FRACP PhD
Head of Oncology Clinical Trials
Genitourinary Cancer

Associate Professor Michael Franco MBBS FRACP FAChPM
Head of Oncology Operations & Education
Palliative Medicine Breast & GI Cancer

Associate Professor Jake Shortt BMedSc MBChB FRACP FRCPA PhD
Head of Haematology Research

Dr. Michelle White MBBS GDipPallMed FRACP
Head of Oncology Quality & Safety, Breast Cancer

Senior Medical Staff (listed in alphabetical order)
Dr. Muhammad Alamgeer MBBS MRCP FRACP MD
Lung, Head & Neck Cancer

Associate Professor Vinod Ganju MBBS FRACP
Breast & Lung Cancer

Dr. Geraldine Goss MBBS FRACP MD MMED
Gynaecological Oncology

Dr. Marion Harris MBBS FRACP
Director of Familial Cancer, GI and Breast Cancer

Dr. Edmond Kwan MBBS FRACP
Genitourinary Cancer

Dr. Ben Markman MBBS FRACP
Phase 1 Trials, Lung, Gastrointestinal Cancers

Dr. David Pook BMedSci (Hons) MBBS FRACP MD
Genitourinary Cancer

Dr. Ranjana Srivastava MBBS FRACP
Breast, Gastrointestinal Cancers, Geriatric Oncology

Associate Professor Andrew Strickland MBBS FRACP
Gastrointestinal Cancers


Mrs. Irina Arzhintar
Acting Unit Manager

Ms. Cheryl-Ann Hawkins
Study Coordinator

Ms. Penny McGuire
Study Coordinator

Ms. Chris Brooks
Study Coordinator

Ms. Louise Davis
Study Coordinator

Ms. Chris Poole
Study Coordinator

Ms. Laima Muceneikas
Study Coordinator

Ms. Lindsay Thompson
Study Coordinator

Ms. Shelly Firth
Study Coordinator

Ms. Lisa Robinson
Study Coordinator

Ms. Kim Brewin
Study Coordinator

Ms. Fran Bishop
Study Coordinator

Ms. Stephanie Kaladis
Lab Scientist

Ms. Joanna Maggs
Ethics Submission Specialist

Ms. Sabah Saad
Ethics Submission Specialist

Ms. Isabel Nehma
Clinical Trial Assistant

Ms. Joyce Zheng
Clinical Trial Assistant

Ms. Lauren Curtain
Clinical Trial Assistant


Dr. Ramin Behzadigohar MBBS MD FRACP


Dr. Siddharth Menon MBBS
Dr. Cameron McLaren MBBS BSc (Hons)
Dr. Christine Muttiah MBBS


Ms. Annette McClellan
Oncology department Secretary/PA to Professor Segelov.
E: Annette.McClellan@monashhealth.org
P: +61 3 8572 2392

 

Department Publications

2017
Szczepny A, Rogers S, Jayasekara WS, Park K, McCloy RA, Cochrane CR, Ganju V, Cooper WA, Sage J, Peacock CD, Cain JE. The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer. Oncogene. 2017 Jun 5.

Chan DL, Segelov E, Wong RS, Smith A, Herbertson RA, Li BT, Tebbutt N, Price T, Pavlakis N. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. The Cochrane database of systematic reviews. 2017 Jun 27;6:CD007047.

Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O’Dorisio TM, Salem R, Segelov E, Howe JR. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017 Jul 1;46(6):707-14.

Chüeh AC, Liew MS, Russell PA, Walkiewicz M, Jayachandran A, Starmans MH, Boutros PC, Wright G, Barnett10 SA, Mariadason JM, John T. Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. transfer. 2017 May 23;11:12.

Singh S, Chan DL, Moody L, Carsley S, Metz DC, Strosberg JR, Segelov E. Development of follow up recommendations for completely resected gastroenteropancreatic neuroendocrine tumours (GEP-NETS): Practice Survey of Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) in conjunction with North American Neuroendocrine Tumour Society (NANETS).

Segelov E, Thavaneswaran S, Waring P, Desai J, Mann K, Elez E, Chantrill L, Pavlakis N, Nott L, Underhill C, Khasraw M. 32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation–analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. European Journal of Cancer. 2015 Sep 1;51:S726

Chan D, Ferone D, Albertelli M, Segelov E, Singh S. Escalated dose somatostatin analogues (SSAs) in management of neuroendocrine tumors (NETs): A systematic review.

Submitted
Smith K, Winstanley J, Boyle F, O’Reilly A, White M, Antill Y. Eyelashes and Eyebrow Madarosis: A qualititative study to assess the perceptions and experience of Australian patients with early breast cancer. Submitted to Supportive Care September 2016

2016
Woodward N, White M, Pugliano L, Tsoi D, Ryan C. Management of patients treated with pertuzumab in the Australian clinical practice setting. Asia‐Pacific Journal of Clinical Oncology. 2016 Jun 1;12(S2):5-15.

Isaacs C, O'Regan R, Xu B, Masuda N, Arena F, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M. Abstract P4-13-12: Everolimus plus trastuzumab and vinorelbine for trastuzumab-resistant, taxane-pretreated, HER2+ advanced breast cancer: Overall survival results from BOLERO-3.

 

Optimal Care Pathways for cancer patients

The optimal cancer care pathways (OCPs) describe the optimal cancer care for specific tumour types. They map the patient journey, aiming to foster an understanding of the whole pathway and its distinct components to promote quality cancer care and patient experiences.

Cancer: What to Expect? Information for patients at http://www.cancerpathways.org.au/

Information for clinicians at http://www.cancervic.org.au/for-health-professionals/optimal-care-pathways

 

Contacts and Locations
Moorabbin Hospital
Centre Rd, Bentleigh East
+61 3 9928-8120

Clinical Trials Centre
Level 3, MHTP Building
Monash Health, Clayton
+ 61 3 8572 2400

Dandenong Hospital
David St, Dandenong
+61 3 9554-8977